IRIS
PAOLICELLI, DAMIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.817
AS - Asia 3.478
EU - Europa 2.442
SA - Sud America 972
AF - Africa 263
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 8
Totale 14.989
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.680
SG - Singapore 1.352
CN - Cina 798
BR - Brasile 758
IT - Italia 469
HK - Hong Kong 458
RU - Federazione Russa 395
SE - Svezia 385
VN - Vietnam 302
DE - Germania 248
FR - Francia 220
GB - Regno Unito 192
FI - Finlandia 164
UA - Ucraina 118
CI - Costa d'Avorio 109
IN - India 109
AR - Argentina 79
BD - Bangladesh 73
CA - Canada 65
ID - Indonesia 62
NL - Olanda 54
JP - Giappone 53
ZA - Sudafrica 44
IQ - Iraq 43
BE - Belgio 41
MX - Messico 41
PK - Pakistan 37
TR - Turchia 34
VE - Venezuela 33
CO - Colombia 29
EC - Ecuador 29
ES - Italia 27
PL - Polonia 27
SA - Arabia Saudita 26
AT - Austria 23
TN - Tunisia 22
PH - Filippine 21
UZ - Uzbekistan 19
MA - Marocco 18
CL - Cile 15
RO - Romania 13
EG - Egitto 11
JO - Giordania 11
KE - Kenya 11
LT - Lituania 10
AE - Emirati Arabi Uniti 9
PY - Paraguay 9
UY - Uruguay 9
AU - Australia 8
CZ - Repubblica Ceca 8
ET - Etiopia 8
MY - Malesia 8
OM - Oman 8
AZ - Azerbaigian 7
DZ - Algeria 7
IR - Iran 7
KZ - Kazakistan 7
NP - Nepal 7
PA - Panama 7
SN - Senegal 7
AL - Albania 6
DO - Repubblica Dominicana 6
IE - Irlanda 6
JM - Giamaica 6
PE - Perù 6
BG - Bulgaria 5
BO - Bolivia 5
CR - Costa Rica 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
PT - Portogallo 5
EU - Europa 4
HU - Ungheria 4
IL - Israele 4
NG - Nigeria 4
CH - Svizzera 3
GR - Grecia 3
HR - Croazia 3
SC - Seychelles 3
A1 - Anonimo 2
AO - Angola 2
BS - Bahamas 2
DK - Danimarca 2
KR - Corea 2
LB - Libano 2
MK - Macedonia 2
MZ - Mozambico 2
RS - Serbia 2
RW - Ruanda 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BF - Burkina Faso 1
BH - Bahrain 1
BJ - Benin 1
CG - Congo 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
Totale 14.964
Salva come PNG Salva come JPEG
Città #
Fairfield 893
Ashburn 825
Singapore 720
Woodbridge 603
Chandler 514
Hong Kong 458
Houston 426
Seattle 402
San Jose 396
Cambridge 311
Wilmington 305
Nyköping 290
Beijing 258
Jacksonville 226
Ann Arbor 224
Dallas 171
Lauterbourg 139
New York 126
Lawrence 117
Bari 116
Los Angeles 115
Roxbury 114
Abidjan 109
Ho Chi Minh City 95
Nanjing 94
Helsinki 75
Boardman 74
Des Moines 73
Princeton 68
Brooklyn 58
Munich 55
São Paulo 55
Santa Clara 54
Council Bluffs 52
Buffalo 51
Hanoi 51
Tokyo 51
Inglewood 49
Chicago 46
London 42
Brussels 40
Moscow 40
San Diego 39
Frankfurt am Main 37
Jakarta 36
Orem 35
Falkenstein 34
Nuremberg 33
Rio de Janeiro 28
Toronto 27
Nanchang 25
Shenyang 24
Amsterdam 23
Guangzhou 22
Johannesburg 22
Warsaw 21
Atlanta 20
Belo Horizonte 20
Dong Ket 20
Montreal 20
Norwalk 20
Baghdad 18
Denver 18
Tianjin 18
Chennai 17
Hebei 17
Jiaxing 17
Paris 17
Phoenix 17
San Francisco 17
Milan 15
Shanghai 15
Stockholm 15
Haiphong 14
Lahore 14
Poplar 14
Tashkent 14
Bisceglie 13
Caracas 13
Dhaka 13
Rome 13
Boston 12
Brasília 12
Buenos Aires 12
Marseille 12
North Bergen 12
Salt Lake City 12
Wuhan 12
Da Nang 11
Manchester 11
Mexico City 11
Changsha 10
Jeddah 10
Medellín 10
Mottola 10
New Delhi 10
Porto Alegre 10
Pune 10
Recife 10
Tunis 10
Totale 10.003
Salva come PNG Salva come JPEG
Nome #
Signs and symptoms of COVID-19 in patients with multiple sclerosis 210
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 206
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 191
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 189
A rare association between multiple sclerosis and Charcot-Marie-Tooth type 1B 180
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 179
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 179
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 179
Prognostic indicators in pediatric clinically isolated syndrome 179
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 178
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 177
Age-related changes of serum N-acetyl-aspartate in healthy controls. 175
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 166
Age-related disability in multiple sclerosis 165
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 165
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 159
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 157
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 155
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 154
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 148
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 143
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 142
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 142
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 136
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 132
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 132
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 130
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 127
A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study. 126
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. 125
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. 125
Multiple Sclerosis Progression and Relapse Activity in Children 123
Atypical forms of Multiple Sclerosis or different phases of a same disease? 122
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 122
ADHESION MOLECULES AND MATRIX METALLOPROTEINASES IN MS: EFFECTS INDUCED BY INTERFERON BETA 118
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 118
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 116
Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis 116
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 115
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 114
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 114
Magnetoencephalography and high‐density electroencephalography study of acoustic event related potentials in early stage of multiple sclerosis: A pilot study on cognitive impairment and fatigue 113
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 112
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 112
Patient expression of emotions and neurologist responses in first multiple sclerosis consultations 111
Low serum urate levels are associated to female gender in multiple sclerosis patients. 111
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 111
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 111
Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients 110
null 109
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. 109
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 109
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 108
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 108
Predictors of disability worsening in clinically isolated syndrome 107
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 105
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 104
A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva® PSP 104
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. 104
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 101
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 101
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 101
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 100
The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. 100
Geographical variations in sex ratio trends over time in multiple sclerosis. 98
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study 98
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. 97
CHANGES OF SERUM ICAM-1 AND MMP-9 INDUCED BY RIFNB-1B TREATMENT IN RELAPSING-REMITTING MS 95
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. 95
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients 94
A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review 93
Variations of the perforin gene in patients with multiple sclerosis. 93
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 93
Macular ganglion cell-inner plexiform layer defect patterns in multiple sclerosis patients without optic neuritis: A Spectral-Domain-Optical Coherence Tomography Cross-Sectional, Case-Control, Pilot Study 92
Coverage of the requirements of first and second level stroke unit in Italy 90
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 88
Informing MS patients on treatment options: a consensus on the process of consent taking 88
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy 86
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 84
RIFNB DOWNREGULATES TNFA-INDUCED ICAM-1 EXPRESSION ON BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BEMC) AND INCREASES SERUM SOLUBLE ICAM-1 (SICAM-1) IN RR MS 83
CHANGES OF SERUM SOLUBLE ICAM-1 AND MATRIX METALLOPROTEINASE-9 DURING INTERFERON BETA-1B TREATMENT IN RR MS 82
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study 82
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 81
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 81
Modificazioni dei livelli sierici di ICAM-1 solubile (sICAM.1), e Gelatinasi A e B e sottopopolazioni T-linfocitarie di sangue periferico indotte dal trattamento con interferone-beta-1b (IFN-BETA-1B) in pazienti con Sclerosi Multipla (SM) Relapsing-Remitting (RR): Relazione con la produzione di anticorpi neutralizzanti anti-interferone (NABs) 79
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. 79
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia 78
The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. 78
Acoustic Voice Analysis as a Useful Tool to Discriminate Different ALS Phenotypes 78
Immunomodulatory therapies delay disease progression in multiple sclerosis. 74
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study) 74
null 73
Changes of serum sICAM-1 and MMP-9 induced by rIFN beta-1b treatment in relapsing-remitting MS 73
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. 73
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. 72
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: A 18-month multicentre study 72
null 71
Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics 70
Risk of Getting COVID-19 in People With Multiple Sclerosis 70
The IFN beta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy 69
Totale 11.566
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.190
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.190
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021379 0 0 0 0 0 0 0 0 0 166 125 88
2021/2022936 57 109 16 33 44 88 43 46 86 59 173 182
2022/20231.382 225 178 83 122 162 162 17 165 204 5 26 33
2023/2024461 57 66 28 29 37 108 13 18 8 23 6 68
2024/20252.782 133 42 180 102 75 246 257 223 133 166 424 801
2025/20265.435 842 357 436 736 652 360 642 213 664 533 0 0
Totale 15.482